Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of PCSK9 inhibitors and statins on cholesterol and bile acid metabolism
2023-505726-34-02Phase 4Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of evolocumab and atorvastatin, sponsored by Karolinska University Hospital. Primary endpoints: Changes in parameters of cholesterol metabolism and Changes in parameters of bile acid metabolism. Planned start Apr 2024; status: authorised.
02
Drugs
evolocumabatorvastatin
Beyond the preview
Go deeper on 2023-505726-34-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505726-34-02.